Earnings To Watch: Standard BioTools Inc (LAB) Reports Q3 2025 Result
This article first appeared on GuruFocus.
Standard BioTools Inc (NASDAQ:LAB) is set to release its Q3 2025 earnings on Nov 4, 2025. The consensus estimate for Q3 2025 revenue is $18.00 million, and the earnings are expected to come in at -$0.06 per share. The full year 2025's revenue is expected to be $86.36 million and the earnings are expected to be -$0.24 per share. More detailed estimate data can be found on the Forecast page.
Warning! GuruFocus has detected 5 Warning Signs with LAB.
Is LAB fairly valued? Test your thesis with our free DCF calculator.
Revenue estimates for Standard BioTools Inc (NASDAQ:LAB) have declined from $169.15 million to $86.36 million for the full year 2025 and from $189.75 million to $79.73 million for 2026 over the past 90 days. Earnings estimates have improved, increasing from -$0.28 per share to -$0.24 per share for the full year 2025 and from -$0.17 per share to -$0.12 per share for 2026 over the past 90 days.
In the previous quarter ending on June 30, 2025, Standard BioTools Inc's (NASDAQ:LAB) actual revenue was $21.76 million, which missed analysts' revenue expectations of $39.82 million by -45.35%. The company's actual earnings were -$0.09 per share, missing analysts' earnings expectations of -$0.08 per share by -12.50%. After releasing the results, Standard BioTools Inc (NASDAQ:LAB) was up by 2.34% in one day.
Based on the one-year price targets offered by 2 analysts, the average target price for Standard BioTools Inc (NASDAQ:LAB) is $1.78, with a high estimate of $2.00 and a low estimate of $1.55. The average target implies an upside of 47.92% from the current price of $1.20.
Based on GuruFocus estimates, the estimated GF Value for Standard BioTools Inc (NASDAQ:LAB) in one year is $0.40, suggesting a downside of -66.67% from the current price of $1.20.
Based on the consensus recommendation from 3 brokerage firms, Standard BioTools Inc's (NASDAQ:LAB) average brokerage recommendation is currently 2.3, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies strong buy, and 5 denotes sell.